



IPW

Practitioner's Docket No. MPI02-202P1RNM

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	George Mulligan et al.		
Application No.:	10/728,055	Group No.:	1642
Filed:	December 4, 2003	Examiner:	Reddig, Peter J.
For:	METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND TREATMENT OF PATIENTS WITH PROTEASOME INHIBITION THERAPY		

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT TRANSMITTAL**

1. Transmitted herewith for this application are:
  - a. This Amendment and Response to Restriction Requirement Transmittal (2 pages, in duplicate);
  - b. Amendment and Response to Restriction Requirement (5 pages);
  - c. Transmittal of Supplemental Information Disclosure Statement (3 pages);
  - d. Supplemental Information Disclosure Statement (2 pages);
  - e. Form PTO/SB/08B (1 page) with copies of references C10-C14; and
  - f. Return receipt postcard.

**STATUS**

2. Applicant is other than a small entity.

**PETITION FOR EXTENSION OF TIME**

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(3)) for a four month extension:

Fee: \$,1590.00  
Extension fee due with this request \$1,590.00

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"  
Mailing Label No.

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office (571-273-8300).

Signature

Sean Hunziker/Beverly Sotiropoulos  
(type or print name of person certifying)

Date: June 7, 2007

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

06/12/2007 HGU/TE/AL 00000073 501668 10728055

01 FC:1254 1590.00 DA

**Practitioner's Docket No. MPI02-202P1RM**

If an additional extension of time is required, please consider this a petition therefor.

**FEE FOR CLAIMS**

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	OTHER THAN A SMALL ENTITY
Claims Remaining After Amendment	Highest No. Previously Paid For	Present Extra	
		Rate	Addit. Fee
Total 12	Minus 28	= 0	\$50.00 = \$0.00
Indep. 1	Minus 4	= 0	\$200.00 = \$0.00
First Presentation of Multiple Dependent Claims	No	\$360.00	= \$0.00
		Total Addit. Fee	\$0.00
Total additional fee for claims required			\$0.00
<b>FEE PAYMENT</b>			

5. Charge Account No. 501668 the sum of \$1,590.00 (which includes the \$1,590.00 extension fee and the \$0.00 additional fee for claims). A duplicate of this transmittal is attached.

**FEE DEFICIENCY**

6. If any additional extension and/or fee is required, charge Account No. 501668.  
If any additional fee for claims is required, charge Account No. 501668.

7. Correspondence Address

Direct all future correspondence to:

Customer Number 30405  
OR  
Intellectual Property Department  
MILLENNIUM PHARMACEUTICALS, INC.  
40 Landsdowne Street  
Cambridge, MA 02139

June 7, 2007

MILLENNIUM PHARMACEUTICALS, INC.

By *Tracy M. Sioussat*  
Tracy M. Sioussat, Ph.D.  
Registration No. 50,609  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-374-7679  
Facsimile - 617-551-8820